Precision BioSciences Announces Purchase of Common Shares by Management for $300,000 in Private Placement

DURHAM, North Carolina, May 8, 2024–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL) (the “Company”), an advanced gene editing company utilizing its proprietary new product ARCUS® platform to develop in vivo gene editing therapies for sophisticated genetic modifications, including gene insertion, deletion and excision, today announced that it has entered into a definitive subscription agreement, under which the Company will issue and sell in the framework of a private placement without intermediary to members of its managers. the management team, including the CEO, 25,000 shares of common stock at a price of $12.00 per share, representing a premium of 13.5% to the closing price of its common stock immediately preceding signing of the subscription agreement, for a total amount of $300,000 (the “Private Placement”). The private placement is expected to close on May 8, 2024, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from this offering to support its ongoing research and development initiatives.

There is no placement agent for the Private Placement.

The offer and sale of the securities has not been and will not be registered under the Securities Act of 1933, as amended, or any other securities laws. The securities may not be offered or sold except pursuant to an exemption or in a transaction not subject to the registration requirements of the Securities Act and any other applicable securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale of these titles would be illegal. prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its new proprietary product ARCUS.® genome editing platform which differs from other technologies by its way of cutting, its reduced size and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to achieve better and more defined therapeutic outcomes. Thanks to ARCUS, the company’s pipeline consists of in vivo gene editing candidates designed to provide lasting cures for the widest range of genetic and infectious diseases for which no adequate treatment exists.

Forward-looking statements

Certain statements contained in this press release, including those relating to the timing and size of the Private Placement, the anticipated total gross proceeds of the Private Placement and other statements relating to the Private Placement, are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties associated with consummation of the Private Placement, uncertainties related to market conditions, satisfaction of customary closing conditions associated with the Private Placement, consummation of the Private Placement on anticipated terms or at all, general economic conditions and other risks identified from time to time in the reports the Company files with the SEC, including its most recent annual report on Form 10-K, its quarterly reports on Form 10-Q and its current report. Reports on Form 8-K, available at The forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise these statements. The Company’s operations are subject to significant risks and uncertainties, including those discussed above. Investors, potential investors and others should pay particular attention to these risks and uncertainties.

View source version on


Investor and media contact:
Naresh Tanna
Vice President of Investor Relations
[email protected]